Applied Therapeutics (APLT) News Today → Look Who Fired the World’s Richest Man (From Banyan Hill Publishing) (Ad) Free APLT Stock Alerts $4.64 +0.21 (+4.74%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 1:08 PM | marketbeat.comApplied Therapeutics (NASDAQ:APLT) Shares Gap Down to $4.43Applied Therapeutics (NASDAQ:APLT) Shares Gap Down to $4.43May 10, 2024 | finance.yahoo.comApplied Therapeutics Inc (APLT) Reports Q1 2024 Earnings: A Deep Dive into Financials and ...May 9, 2024 | investorplace.comAPLT Stock Earnings: Applied Therapeutics Meets EPS, Misses Revenue for Q1 2024May 9, 2024 | msn.comApplied Therapeutics GAAP EPS of -$0.67 misses by $0.51May 9, 2024 | globenewswire.comApplied Therapeutics Reports First Quarter 2024 Financial ResultsMay 7, 2024 | finance.yahoo.comApplied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceApril 17, 2024 | marketbeat.comApplied Therapeutics (NASDAQ:APLT) Stock Price Down 3.3%Applied Therapeutics (NASDAQ:APLT) Stock Price Down 3.3%April 16, 2024 | marketbeat.comApplied Therapeutics (NASDAQ:APLT) Trading 4.2% Higher Applied Therapeutics (NASDAQ:APLT) Shares Up 4.2%April 15, 2024 | globenewswire.comApplied Therapeutics Appoints Dale Hooks as Chief Commercial OfficerApril 14, 2024 | markets.businessinsider.comRBC Capital Sticks to Their Buy Rating for Applied Therapeutics (APLT)April 13, 2024 | marketbeat.comApplied Therapeutics, Inc. (NASDAQ:APLT) Sees Significant Increase in Short InterestApplied Therapeutics, Inc. (NASDAQ:APLT - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 4,980,000 shares, an increase of 31.4% from the March 15th total of 3,790,000 shares. Based on an average trading volume of 2,070,000 shares, the days-to-cover ratio is presently 2.4 days.April 9, 2024 | marketbeat.comApplied Therapeutics (NASDAQ:APLT) Shares Down 3.7% Applied Therapeutics (NASDAQ:APLT) Trading Down 3.7%April 6, 2024 | investing.comApplied Therapeutics reveals Phase 3 data on heart drugApril 4, 2024 | finance.yahoo.comApplied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024April 3, 2024 | marketbeat.comApplied Therapeutics (NASDAQ:APLT) Trading Down 2.8%Applied Therapeutics (NASDAQ:APLT) Trading Down 2.8%April 3, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Applied Therapeutics (APLT) and Vincerx Pharma Inc (VINC)April 1, 2024 | benzinga.comFDA Presses Delay Button For Applied Therapeutics' First Potential Marketed Drug For Rare DiseaseApril 1, 2024 | marketbeat.comApplied Therapeutics (NASDAQ:APLT) Shares Gap Down to $6.80Applied Therapeutics (NASDAQ:APLT) Shares Gap Down to $6.80April 1, 2024 | benzinga.comWhy Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving PremarketMarch 29, 2024 | markets.businessinsider.comApplied Therapeutics Says FDA Extends Review Period Of NDA For GovorestatMarch 28, 2024 | finance.yahoo.comUPDATE 1-US FDA extends review of Applied Therapeutics' genetic disease drugMarch 28, 2024 | reuters.comUS FDA extends review of Applied Therapeutics' genetic disease drugMarch 28, 2024 | globenewswire.comApplied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic GalactosemiaMarch 26, 2024 | marketbeat.comApplied Therapeutics (NASDAQ:APLT) Now Covered by Royal Bank of CanadaRoyal Bank of Canada initiated coverage on shares of Applied Therapeutics in a report on Tuesday. They set an "outperform" rating and a $12.00 price target on the stock.March 25, 2024 | marketbeat.comApplied Therapeutics (NASDAQ:APLT) Shares Gap Down to $6.75Applied Therapeutics (NASDAQ:APLT) Shares Gap Down to $6.75March 20, 2024 | marketbeat.comApplied Therapeutics (NASDAQ:APLT) Shares Up 4.6%Applied Therapeutics (NASDAQ:APLT) Trading Up 4.6%March 20, 2024 | investing.comApplied therapeutics CCO sells shares worth over $263kMarch 20, 2024 | investing.comApplied therapeutics CFO sells shares worth over $150kMarch 19, 2024 | marketbeat.comApplied Therapeutics (NASDAQ:APLT) Shares Gap Down Following Insider SellingApplied Therapeutics (NASDAQ:APLT) Shares Gap Down Following Insider SellingMarch 19, 2024 | insidertrades.comInsider Selling: Applied Therapeutics, Inc. (NASDAQ:APLT) CFO Sells 28,727 Shares of StockMarch 19, 2024 | insidertrades.comApplied Therapeutics, Inc. (NASDAQ:APLT) CEO Shoshana Shendelman Sells 318,573 SharesMarch 18, 2024 | marketbeat.comLeslie D. Funtleyder Sells 28,727 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) StockApplied Therapeutics, Inc. (NASDAQ:APLT - Get Free Report) CFO Leslie D. Funtleyder sold 28,727 shares of the firm's stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $5.39, for a total value of $154,838.53. Following the completion of the sale, the chief financial officer now owns 308,421 shares in the company, valued at $1,662,389.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.March 18, 2024 | marketbeat.comApplied Therapeutics (NASDAQ:APLT) Price Target Increased to $13.00 by Analysts at UBS GroupUBS Group lifted their price target on Applied Therapeutics from $12.00 to $13.00 and gave the company a "buy" rating in a research report on Friday.March 11, 2024 | marketbeat.comLeerink Partnrs Research Analysts Increase Earnings Estimates for Applied Therapeutics, Inc. (NASDAQ:APLT)Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) - Research analysts at Leerink Partnrs raised their Q1 2024 EPS estimates for Applied Therapeutics in a research note issued on Wednesday, March 6th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings perMarch 10, 2024 | marketbeat.comSchonfeld Strategic Advisors LLC Makes New $1.14 Million Investment in Applied Therapeutics, Inc. (NASDAQ:APLT)Schonfeld Strategic Advisors LLC acquired a new position in Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 457,400 shares of the company's stock, vMarch 8, 2024 | marketbeat.comApplied Therapeutics (NASDAQ:APLT) Trading 6.5% Higher Applied Therapeutics (NASDAQ:APLT) Trading Up 6.5%March 8, 2024 | finance.yahoo.comApplied Therapeutics Inc (APLT) Announces Year-End 2023 Financial Results and Clinical ProgressMarch 6, 2024 | marketbeat.comUBS Group Increases Applied Therapeutics (NASDAQ:APLT) Price Target to $12.00UBS Group lifted their price target on Applied Therapeutics from $4.00 to $12.00 and gave the company a "buy" rating in a research note on Wednesday.March 6, 2024 | marketbeat.comWorth Venture Partners LLC Makes New $483,000 Investment in Applied Therapeutics, Inc. (NASDAQ:APLT)Worth Venture Partners LLC acquired a new position in shares of Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 193,973 shares of the company's stocMarch 6, 2024 | globenewswire.comApplied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial ResultsMarch 5, 2024 | marketbeat.comApplied Therapeutics (NASDAQ:APLT) Trading Down 5.7%Applied Therapeutics (NASDAQ:APLT) Trading Down 5.7%March 3, 2024 | marketbeat.comArmistice Capital LLC Takes Position in Applied Therapeutics, Inc. (NASDAQ:APLT)Armistice Capital LLC bought a new stake in shares of Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 3,400,000 shares of the company's stock, valued at approximately $8,4March 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Applied Therapeutics as FDA Prioritizes Govorestat, Signaling Strong Market ProspectsMarch 1, 2024 | markets.businessinsider.comOptimistic Buy Rating for Applied Therapeutics Amid Favorable Drug Approval Prospects and Strong Financial PositionFebruary 28, 2024 | marketwatch.comApplied Therapeutics Shares Surge on FDA Review, $100 Million Funding RoundFebruary 28, 2024 | markets.businessinsider.comApplied Therapeutics Rallies After Announcing Private Placement Of SharesFebruary 28, 2024 | msn.comFDA Grants Review Date For Applied Therapeutics' First Commercial Product For Rare Metabolic DisorderFebruary 28, 2024 | marketbeat.comApplied Therapeutics (NASDAQ:APLT) Reaches New 1-Year High at $9.39Applied Therapeutics (NASDAQ:APLT) Reaches New 1-Year High at $9.39February 28, 2024 | investorplace.comWhy Is Applied Therapeutics (APLT) Stock Up 59% Today?February 28, 2024 | globenewswire.comApplied Therapeutics Announces $100 Million Private Placement Get Applied Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden FINISHED On June 13th? (Ad)Thanks to Biden’s disgraceful leadership we now have sky-high inflation… unchecked immigration… rampant crime… and a “woke mob” hell bent on destroying the America you and I know and love. Biden’s days are numbered. Click here now to see his shocking evidence. APLT Media Mentions By Week APLT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLT News Sentiment▼0.170.57▲Average Medical News Sentiment APLT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLT Articles This Week▼92▲APLT Articles Average Week Get Applied Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Astria Therapeutics News Avid Bioservices News Arbutus Biopharma News Aerovate Therapeutics News COMPASS Pathways News ArriVent BioPharma News Larimar Therapeutics News IGM Biosciences News Verve Therapeutics News Altimmune News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APLT) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityThe only AI company you should be looking atBehind the MarketsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Applied Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
